Lycort Tablet contains Deflazacort 6 mg, a corticosteroid with potent anti-inflammatory and immunosuppressive properties. It is primarily indicated for the management of various inflammatory and autoimmune conditions such as rheumatoid arthritis, systemic lupus erythematosus, polymyalgia rheumatica, and certain allergic disorders. Deflazacort exerts its therapeutic effects by modulating the immune response and reducing inflammation through inhibition of multiple inflammatory mediators. Lycort is also utilized in the treatment of specific muscular dystrophies to improve muscle strength and function. The drug is administered orally and should be taken under strict medical supervision due to potential side effects associated with corticosteroid therapy, including immunosuppression, hyperglycemia, osteoporosis, and adrenal suppression. Dosage and duration of treatment must be individualized based on the patient’s clinical condition and response to therapy. Gradual tapering is recommended to prevent withdrawal symptoms and adrenal insufficiency. Patients should be monitored regularly for adverse effects, and concomitant use with other immunosuppressants requires careful consideration. Lycort Tablet is contraindicated in systemic fungal infections and hypersensitivity to deflazacort or any excipients. Proper adherence to prescribed dosage and medical guidance ensures optimal therapeutic outcomes while minimizing risks.